ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims

The complaint alleges that ADMA Biologics misled shareholders by failing to disclose critical operational issues during the specified period. Plaintiffs contend that the company engaged in undisclosed related-party transactions and utilized channel stuffing to artificially inflate revenue figures. Furthermore, the lawsuit asserts that ADMA lacked the necessary internal controls to sustain its reported growth, rendering the company’s public statements about its business prospects materially inaccurate.

While no class has been certified at this stage, shareholders who acquired securities during the relevant window may choose to participate in the litigation or remain absent class members. Those interested in seeking recovery for their losses must file a motion with the court by the August 10 deadline. Glancy Prongay Wolke & Rotter LLP, a firm noted for its work in securities litigation, is currently soliciting participants for the action.